Levofloxacin
- Generic Name
- Levofloxacin
- Brand Names
- Levaquin, Quinsair
- Drug Type
- Small Molecule
- Chemical Formula
- C18H20FN3O4
- CAS Number
- 100986-85-4
- Unique Ingredient Identifier
- RIX4E89Y14
- Background
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along w...
- Indication
In oral and intravenous formulations, levofloxacin is indicated in adults for the treatment of various infections caused by susceptible bacteria, including infections of the upper respiratory tract, lower respiratory tract, skin, skin structures, urinary tract, and prostate. The oral formulation is also indicated in both adults and children 6 months of age a...
- Associated Conditions
- Abscesses caused by susceptible bacteria, Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible bacteria, Acute Pyelonephritis caused by Infection Due to Escherichia Coli, Bacterial Conjunctivitis caused by susceptible bacteria, Cellulitis caused by susceptible bacteria, Community Acquired Pneumonia (CAP) caused by susceptible bacteria, Furuncle caused by susceptible bacteria, Impetigo caused by susceptible bacteria, Inhalational Anthrax, Nosocomial Pneumonia caused by Pseudomonas Infections, Nosocomial Pneumonia caused by susceptible bacteria, Plague caused by Yersinia pestis, Pyoderma caused by susceptible bacteria, Wound Infections caused by susceptible bacteria, Acute bacterial sinusitis caused by susceptible bacteria, Chronic Bacterial prostatitis caused by susceptible bacteria, Chronic Pseudomonas Infections, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin and skin-structure infections caused by susceptible bacteria, Uncomplicated Urinary Tract Infection caused by susceptible bacteria, Uncomplicated skin and skin-structure infections caused by susceptible bacteria
- Associated Therapies
- -
Enteroaggregative E.Coli (EAEC)
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2016-12-26
- Target Recruit Count
- 5
- Registration Number
- NCT00362869
- Locations
- 🇺🇸
University of Texas Health Science Center, Houston, Texas, United States
Levofloxacin, Chronic Bacterial Prostatitis
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2007-10-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 120
- Registration Number
- NCT00277511
- Locations
- 🇩🇪
Sanofi-Aventis, Berlin, Germany
A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Cefuroxime Axetil in the Treatment of Adults With Persistent Bronchitis Experiencing Rapid Onset of Severe Worsening of Symptoms Caused by Bacteria
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2011-06-10
- Target Recruit Count
- 485
- Registration Number
- NCT00269932
A Study of the Safety and Effectiveness of Levofloxacin Compared With Lomefloxacin in the Treatment of Complicated Urinary Tract Infections
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-24
- Last Posted Date
- 2011-06-10
- Target Recruit Count
- 603
- Registration Number
- NCT00258102
A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-24
- Last Posted Date
- 2011-05-23
- Target Recruit Count
- 578
- Registration Number
- NCT00258089
A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Uncomplicated Infections of the Skin and the Supportive Layers Beneath the Skin
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2011-06-10
- Target Recruit Count
- 361
- Registration Number
- NCT00257062
A Study of the Safety and Effectiveness of Levofloxacin Compared With Cefaclor in the Treatment of Adults With Chronic Bronchitis Experiencing Rapid Onset of Worsening of Symptoms Caused by Bacteria
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2011-06-10
- Target Recruit Count
- 367
- Registration Number
- NCT00257140
A Study of the Safety and Effectiveness of Levofloxacin Compared With Ceftriaxone Sodium or Cefuroxime Axetil in the Treatment of Adults With Pneumonia
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2011-06-10
- Target Recruit Count
- 604
- Registration Number
- NCT00257049
A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Mild to Moderate Infections of the Skin and the Supportive Layers Beneath the Skin
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2011-06-10
- Target Recruit Count
- 431
- Registration Number
- NCT00257036
Study to Demonstrate the Clinical Efficacy of Levofloxacin in the Treatment of Pneumonia
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2008-11-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 460
- Registration Number
- NCT00253955
- Locations
- 🇻🇪
Sanofi-Aventis, Caracas, Venezuela
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath